Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas

Histopathology

Volumn 39, Issue 1, 2001, Pages 43-49

  Holm, R ^a   Skovlund, E ^a   Skomedal, H ^a   Florenes V A ^a   Tanum, G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anal carcinomas and immunohistochemistry; p21; p27

Indexed keywords

PROTEIN P21; PROTEIN P27; TUMOR MARKER; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR DIFFERENTIATION; ANUS TUMOR; BIOSYNTHESIS; CELL CULTURE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0034741793     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2001.01161.x     Document Type: Article

References (39)

1. G1 phase progression: Cyclin on cue
2. Ink4
3. Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer
4. WAF1, a potential mediator of p53 tumor suppression
5. Correlation between p21 expression and clinico-pathological findings, p53 gene and protein alteration, and survival in patients with endometrial carcinomas
6. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
7. p21 (Waf1/cip1) and p53 protein expression in breast cancer
8. WAF1 expression and endocrine response in breast cancer
9. WAF1/CIP1 expression on tumor progression in bladder cancer
10. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung
11. WAF1/CIP1 in adenocarcinoma of the uterine cervix. A possible immunohistochemical marker of a favorable prognosis
12. p21/WAF1 expression in human colorectal carcinoma: Association with p53, transcription factor AP-2 and prognosis
13. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer
14. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia
15. WAF1/CIP1/SD11 gene products in Barrett esophagus and adenocarcinoma of esophagus and esophagogastric junction
16. WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: Relationship with p53 status and proliferative activity
17. A recurrent pattern of chromosomal aberration and immunophenotypic appearance defines anal squamous cell carcinomas
18. Inhibitors of mammalian G1 cyclin-dependent kinases
19. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
20. Kip1 protein: Prognostic implications in primary breast cancer
21. Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma
22. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
23. KIP1 in multistage colorectal carcinogenesis
24. Kip1 levels with recurrence and survival in patients with stage C prostate carcinomas
25. Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers
26. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer
27. KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome
28. Expression of p27/kip1 is down-regulated in human prostate carcinoma progression
29. Anal carcinoma: A clinical approach to p53 and RB gene proteins
30. WAF1/CIP1 in malignant melanoma. Reduced expression in metastatic lesions
31. p21-containing cyclin kinases exist in both active and inactive states
32. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein
33. Prevalence and physical state of human papillomavirus DNA in anal carcinomas
34. TP53 alterations in relationship to cell cycle-associated proteins in p21, cyclin D1, cdk4, RB, MDM2, and EGFR in cancers of the uterine corpus
35. p27 (Kip1) is an inducer of intestinal epithelial cell differentiation
36. Kip1 in non-small lung carcinoma: A prognostic factor independent of ras
37. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma
38. Kip1 in malignant melanoma. Inverse correlation with disease-free survival
39. KIP1 by the human papillomavirus type 16 E7 oncoprotein